Surf Wiki
Save to docs
general/heparins

From Surf Wiki (app.surf) — the open knowledge base

Tinzaparin sodium

Pharmaceutical drug

Pharmaceutical drug

| Drugs.com =

| elimination_half-life = 200 min. for Anti-Xa activity, 257. min for Anti-IIa activity

Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).

It can be given subcutaneously by syringe, or intravenously. It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.

Use in elderly

In July 2008, the company revised the prescribing information to restrict the use of tinzaparin in patients 90 years of age or older. FDA is concerned that the preliminary data from the IRIS study suggests that the increased risk of mortality is not limited only to patients 90 years of age or older.

According to the study Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with chronic kidney disease. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with chronic kidney disease and deep vein thrombosis, pulmonary embolism, or both.

Use in pregnancy

No LMWH, except tinzaparin, is licensed for use in gestational hypercoagulability. Still, tinzaparin is often the LMWH of choice in pregnant women.

Side effects

Bleeding in overdose. There is occasionally bruising at the site of injection.

Monitoring

Tinzaparin does not affect the international normalized ratio (INR), prothrombin time (PT). Anti-factor Xa levels can be measured, and are often used to monitor tinzaparin.

Reversal agent

Protamine sulfate will reverse tinzaparin by 85% per package insert.

References

  • (22)ESHRE April-2011 volume 33 pages 12–13-14
  • e-medicine 2011
  • RCOG March-2010 (Royal college for Obestetric and Gynecology)
  • DVT.org/cardiologist
  • Hull, New England Journal of Medicine, 2010 volume 22 page 19

References

  1. Cheer S.M. et al. Drugs 2004; 64 (13): 1479–1502
  2. Pedersen P.C. et al. Thromb Res 1991; 61 (5-6): 477-487
  3. ''European Pharmacopoeia, 6th Edition, 2008''
  4. Hull et al. NEJM 1992;326,15:975-982
  5. Farmaceutiska Specialiteter i Sverige - the Swedish official drug catalog. [http://www.fass.se Fass.se] {{Webarchive. link. (21 January 2011 > Innohep)
  6. "Drug Shortages List".
  7. "Archived copy".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

heparins
Want to explore this topic further?

Ask Mako anything about Tinzaparin sodium — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report